Cencora, Inc. (NYSE:COR) Shares Sold by Kesler Norman & Wride LLC

Kesler Norman & Wride LLC lessened its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 7.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,727 shares of the company's stock after selling 2,638 shares during the quarter. Cencora makes up about 1.7% of Kesler Norman & Wride LLC's investment portfolio, making the stock its 10th largest holding. Kesler Norman & Wride LLC's holdings in Cencora were worth $7,803,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in COR. Meeder Advisory Services Inc. boosted its holdings in shares of Cencora by 4.1% in the 4th quarter. Meeder Advisory Services Inc. now owns 4,058 shares of the company's stock valued at $912,000 after buying an additional 159 shares during the period. Geode Capital Management LLC raised its position in shares of Cencora by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after purchasing an additional 130,213 shares during the period. HighPoint Advisor Group LLC lifted its holdings in shares of Cencora by 4.2% in the 4th quarter. HighPoint Advisor Group LLC now owns 5,299 shares of the company's stock worth $1,307,000 after purchasing an additional 215 shares during the last quarter. Franklin Resources Inc. boosted its position in Cencora by 1.9% during the 4th quarter. Franklin Resources Inc. now owns 211,076 shares of the company's stock valued at $47,425,000 after purchasing an additional 3,945 shares during the period. Finally, B. Metzler seel. Sohn & Co. AG boosted its position in Cencora by 0.9% during the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 7,389 shares of the company's stock valued at $1,660,000 after purchasing an additional 69 shares during the period. Institutional investors own 97.52% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, Wells Fargo & Company lifted their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

Cencora Price Performance

NYSE:COR traded down $10.07 during midday trading on Friday, hitting $279.29. 4,404,535 shares of the stock were exchanged, compared to its average volume of 1,467,659. The company has a market capitalization of $54.16 billion, a price-to-earnings ratio of 39.73, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a one year low of $214.77 and a one year high of $297.46. The business has a 50-day moving average price of $256.66 and a two-hundred day moving average price of $242.38.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at $85,680,732.63. The trade was a 4.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,675 shares of company stock valued at $8,034,778 over the last ninety days. Corporate insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.